FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912086649> ?p ?o ?g. }

• W2912086649 endingPage "1372" @default.
• W2912086649 startingPage "1363" @default.
• W2912086649 abstract "To compare the efficacy of rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) with traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimens in double-hit lymphoma (DHL) and gene copy number gain (CNG) lymphoma and to contrast the prognosis of these two disease types.We retrospectively examined 127 cases of newly diagnosed diffuse large B-cell lymphoma (DLBCL), and used fluorescence in situ hybridization (FISH) to detect genetic abnormalities in MYC, BCL2, and BCL6.In the two schemes, the 2-year progression-free survival (PFS) was higher for R-DA-EPOCH group than for R-CHOP (79.8% vs 57.5%, P=0.002), this advantage was also reflected in 2-year overall survival (OS) (81.6% vs 58.5%, P=0.002). In double CNG patients, R-DA-EPOCH regimen was significantly better than R-CHOP (P=0.007 for PFS, P=0.010 for OS), and R-DA-EPOCH has the same advantage in DHL patients (P=0.001 for PFS, P=0.047 for OS). For the two disease types, the PFS for DHL was inferior to that for double CNG (52.9% vs 72.4%, P=0.008), while the OS was not significantly different (P=0.050). Subgroup analysis showed that the PFS for double CNG with MYC and BCL2 was superior to that for DHL with MYC and BCL2 (P=0.043), this trend is also seen in double CNG and DHL with MYC and BCL6 (P=0.036). However, the OS was not significantly different between the two subgroups. Multivariate analyses showed that in DLBCL patients with genetic abnormality detected by FISH, the treatment and disease types were independent prognostic factors. The adverse reaction rates were similar in R-DA-EPOCH and R-CHOP (P>0.05).Our retrospective study shows that DHL has a poorer prognosis than double CNG. Based on its improved lifetime and good tolerance, R-DA-EPOCH is a promising regimen for DHL or double CNG, which is expected to become the first-line treatment for high-risk DLBCL types based on more clinical research." @default.
• W2912086649 created "2019-02-21" @default.
• W2912086649 creator A5003547177 @default.
• W2912086649 creator A5007823796 @default.
• W2912086649 creator A5010480280 @default.
• W2912086649 creator A5013014678 @default.
• W2912086649 creator A5019544133 @default.
• W2912086649 creator A5022203410 @default.
• W2912086649 creator A5022526821 @default.
• W2912086649 creator A5026770080 @default.
• W2912086649 creator A5029441253 @default.
• W2912086649 creator A5044104650 @default.
• W2912086649 creator A5048995364 @default.
• W2912086649 creator A5050257179 @default.
• W2912086649 creator A5056422120 @default.
• W2912086649 creator A5056483367 @default.
• W2912086649 creator A5071936531 @default.
• W2912086649 creator A5072036342 @default.
• W2912086649 creator A5080214203 @default.
• W2912086649 creator A5089378544 @default.
• W2912086649 creator A5090591783 @default.
• W2912086649 date "2019-02-01" @default.
• W2912086649 modified "2023-10-13" @default.
• W2912086649 title "<p>Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <em>MYC</em>, <em>BCL2/BCL6</em> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study</p>" @default.
• W2912086649 cites W123492188 @default.
• W2912086649 cites W1543770336 @default.
• W2912086649 cites W1912693401 @default.
• W2912086649 cites W2001923666 @default.
• W2912086649 cites W2023428359 @default.
• W2912086649 cites W2024972915 @default.
• W2912086649 cites W2028850684 @default.
• W2912086649 cites W2029203232 @default.
• W2912086649 cites W2030736011 @default.
• W2912086649 cites W2043622833 @default.
• W2912086649 cites W2054163626 @default.
• W2912086649 cites W2056555760 @default.
• W2912086649 cites W2056641238 @default.
• W2912086649 cites W2076452513 @default.
• W2912086649 cites W2097561270 @default.
• W2912086649 cites W2111827890 @default.
• W2912086649 cites W2119064166 @default.
• W2912086649 cites W2126779872 @default.
• W2912086649 cites W2128710750 @default.
• W2912086649 cites W2133201432 @default.
• W2912086649 cites W2133869962 @default.
• W2912086649 cites W2158267770 @default.
• W2912086649 cites W2159862107 @default.
• W2912086649 cites W2160848167 @default.
• W2912086649 cites W2167805334 @default.
• W2912086649 cites W2280269954 @default.
• W2912086649 cites W2310716991 @default.
• W2912086649 cites W2318772898 @default.
• W2912086649 cites W2484220487 @default.
• W2912086649 cites W2532606512 @default.
• W2912086649 cites W2594626120 @default.
• W2912086649 cites W2724409437 @default.
• W2912086649 cites W2773373071 @default.
• W2912086649 cites W2796143133 @default.
• W2912086649 cites W41459023 @default.
• W2912086649 doi "https://doi.org/10.2147/cmar.s192143" @default.
• W2912086649 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6376881" @default.
• W2912086649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30809101" @default.
• W2912086649 hasPublicationYear "2019" @default.
• W2912086649 type Work @default.
• W2912086649 sameAs 2912086649 @default.
• W2912086649 citedByCount "8" @default.
• W2912086649 countsByYear W29120866492019 @default.
• W2912086649 countsByYear W29120866492020 @default.
• W2912086649 countsByYear W29120866492021 @default.
• W2912086649 countsByYear W29120866492022 @default.
• W2912086649 crossrefType "journal-article" @default.
• W2912086649 hasAuthorship W2912086649A5003547177 @default.
• W2912086649 hasAuthorship W2912086649A5007823796 @default.
• W2912086649 hasAuthorship W2912086649A5010480280 @default.
• W2912086649 hasAuthorship W2912086649A5013014678 @default.
• W2912086649 hasAuthorship W2912086649A5019544133 @default.
• W2912086649 hasAuthorship W2912086649A5022203410 @default.
• W2912086649 hasAuthorship W2912086649A5022526821 @default.
• W2912086649 hasAuthorship W2912086649A5026770080 @default.
• W2912086649 hasAuthorship W2912086649A5029441253 @default.
• W2912086649 hasAuthorship W2912086649A5044104650 @default.
• W2912086649 hasAuthorship W2912086649A5048995364 @default.
• W2912086649 hasAuthorship W2912086649A5050257179 @default.
• W2912086649 hasAuthorship W2912086649A5056422120 @default.
• W2912086649 hasAuthorship W2912086649A5056483367 @default.
• W2912086649 hasAuthorship W2912086649A5071936531 @default.
• W2912086649 hasAuthorship W2912086649A5072036342 @default.
• W2912086649 hasAuthorship W2912086649A5080214203 @default.
• W2912086649 hasAuthorship W2912086649A5089378544 @default.
• W2912086649 hasAuthorship W2912086649A5090591783 @default.
• W2912086649 hasBestOaLocation W29120866491 @default.
• W2912086649 hasConcept C121332964 @default.
• W2912086649 hasConcept C126322002 @default.
• W2912086649 hasConcept C1276947 @default.
• W2912086649 hasConcept C143998085 @default.
• W2912086649 hasConcept C150846664 @default.
• W2912086649 hasConcept C159654299 @default.
• W2912086649 hasConcept C203014093 @default.

• next